MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.
Christopher D BarrettHunter B MooreErnest E MooreDudley Benjamin ChristieSarah OrfanosLorenzo Anez-BustillosRashi JhunjhunwalaSabiha HussainShahzad ShaefiJanice WangNegin HajizadehElias N Baedorf-KassisAmmar Al-ShammaaKrystal CapersValerie M Banner-GoodspeedFranklin L WrightTodd BullPeter K MooreHannah NemecJohn Thomas BuchananCory NonnemacherNatalie RajcooarRamona RamdeoMena YacoubAna GuevaraAileen EspinalLaith HattarAndrew MoracoRobert McIntyreDaniel S TalmorAngela SauaiaMichael B YaffePublished in: Research and practice in thrombosis and haemostasis (2022)
These data suggest tPA is associated with significant improvement in pulmonary function in severe COVID-19 respiratory failure, especially in patients whose pulmonary function is in decline, and has an acceptable safety profile in this patient population.
Keyphrases
- respiratory failure
- coronavirus disease
- sars cov
- extracorporeal membrane oxygenation
- mechanical ventilation
- end stage renal disease
- ejection fraction
- early onset
- newly diagnosed
- chronic kidney disease
- respiratory syndrome coronavirus
- acute respiratory distress syndrome
- prognostic factors
- intensive care unit
- electronic health record
- drug induced
- artificial intelligence
- big data
- patient reported outcomes
- acute ischemic stroke
- machine learning
- patient reported